Literature DB >> 17317021

Ghrelin administered in the early morning increases secretion of cortisol and growth hormone without affecting sleep.

Michael Kluge1, Petra Schüssler, Verena Zuber, Alexander Yassouridis, Axel Steiger.   

Abstract

Ghrelin and growth hormone (GH) releasing hormone (GHRH) both stimulate GH secretion and slow wave sleep (SWS), whereas ghrelin increases, and GHRH decreases cortisol in males. However, GHRH's effect on sleep and cortisol was abolished, on GH mitigated, when administered in the early morning, possibly due to counteracting corticotropin releasing hormone (CRH). Aim of this study was to investigate ghrelin's influence on sleep, GH and cortisol when administered in the early morning. Nocturnal (2000-1000 h) GH and cortisol patterns and polysomnography (2300-1000 h) were determined in 12 healthy males (25.3+/-3.2 yr) twice, receiving 50 microg ghrelin or placebo at 0400, 0500, 0600, and 0700 h, in this single-blind, randomized, cross-over study. The first ghrelin bolus caused the strongest (38.7+/-6.5 ng/ml, placebo: 0.4+/-1.1 ng/ml), second and third smaller, the fourth no GH peak. GH levels remained significantly (p<0.05) higher from 0420-0740 h in the ghrelin condition. Comparably, the first ghrelin bolus caused the strongest cortisol response (156.0+/-12.6 ng/ml; placebo: 78.0+/-10.5 ng/ml). Cortisol was significantly higher from 0440 to 0540 and at 0720 h and decreased thereafter to significantly lower levels (0820-0840 h). Sleep variables did not differ in both conditions. In contrast to GHRH, ghrelin's stimulatory effects were apparently not counteracted (GH), and enhanced (cortisol), respectively, by high CRH in the second half of night.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317021     DOI: 10.1016/j.psyneuen.2006.12.015

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  7 in total

1.  Association Between Self-rating Depression Scores and Total Ghrelin and Adipokine Serum Levels in a Large Population-Based Sample.

Authors:  Dirk Alexander Wittekind; Jürgen Kratzsch; Ronald Biemann; Roland Mergl; Steffi Riedel-Heller; Veronika Witte; Arno Villringer; Michael Kluge
Journal:  Front Psychiatry       Date:  2022-05-11       Impact factor: 5.435

2.  The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans.

Authors:  F Broglio; F Prodam; F Riganti; C Gottero; S Destefanis; R Granata; G Muccioli; T Abribat; A J van der Lely; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 3.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

4.  Nocturnal levels of ghrelin and leptin and sleep in chronic insomnia.

Authors:  Sarosh J Motivala; A Janet Tomiyama; Michael Ziegler; Srikrishna Khandrika; Michael R Irwin
Journal:  Psychoneuroendocrinology       Date:  2008-12-06       Impact factor: 4.905

5.  Central but not systemic administration of ghrelin induces wakefulness in mice.

Authors:  Éva Szentirmai
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

6.  Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants.

Authors:  Roland Ricken; Sandra Bopp; Peter Schlattmann; Hubertus Himmerich; Tom Bschor; Christoph Richter; Samuel Elstner; Thomas J Stamm; Brigitte Schulz-Ratei; Alexandra Lingesleben; Friedel M Reischies; Philipp Sterzer; Stefan Borgwardt; Michael Bauer; Andreas Heinz; Rainer Hellweg; Undine E Lang; Mazda Adli
Journal:  Int J Neuropsychopharmacol       Date:  2017-09-01       Impact factor: 5.176

7.  Association of serum leptin and ghrelin with depressive symptoms in a Japanese working population: a cross-sectional study.

Authors:  Shamima Akter; Ngoc Minh Pham; Akiko Nanri; Kayo Kurotani; Keisuke Kuwahara; Felice N Jacka; Kazuki Yasuda; Masao Sato; Tetsuya Mizoue
Journal:  BMC Psychiatry       Date:  2014-07-30       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.